AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch severity in a phase 2b trial, missing all of its endpoints.